Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360276 | 0.98 | DUT (0.38) | DUTTHRBP2RY14NT5EP2RY12 | |
| SCHEMBL705299 | 0.86 | TDP1 (0.38) | DUTP2RY14NT5EP2RY12P2RY2 | |
| SCHEMBL705298 | 0.84 | TDP1 (0.39) | DUTP2RY14NT5EP2RY12P2RY2 | |
| SCHEMBL6361053 | 0.83 | P2RY14 (0.47) | P2RY14NT5EP2RY2TYMPP2RY4 | |
| SCHEMBL707274 | 0.82 | P2RY14 (0.40) | DUTP2RY14NT5EP2RY12P2RY2 | |
| SCHEMBL6360891 | 0.81 | P2RY14 (0.47) | P2RY14NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL19709161 | 0.80 | TYMP (0.45) | DUTP2RY14P2RY12P2RY2TYMP | |
| SCHEMBL19709156 | 0.80 | TYMP (0.45) | DUTP2RY14P2RY12P2RY2TYMP | |
| SCHEMBL707273 | 0.80 | NT5E (0.41) | P2RY14NT5EP2RY12P2RY2TDP1 | |
| SCHEMBL19692972 | 0.80 | TYMP (0.45) | DUTP2RY14P2RY12P2RY2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002086139-A1 | ANTIBIOTIC AA 896 ANALOGS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | DUT 688/4885THRB 2637/4885P2RY14 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.